Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter CD22 (Epratuzumab Biosimilar) Antikörper

Reaktivität: Human, Cynomolgus, Rhesusaffen FACS, BP, IP Wirt: Kaninchen Monoclonal hL22 unconjugated Recombinant Antibody
Produktnummer ABIN5668217
  • Target Alle CD22 (Epratuzumab Biosimilar) Produkte
    CD22 (Epratuzumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human, Cynomolgus, Rhesusaffen
    Wirt
    • 1
    • 1
    Kaninchen
    Klonalität
    • 2
    Monoklonal
    Konjugat
    • 2
    Dieser CD22 (Epratuzumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    Flow Cytometry (FACS), Blocking Peptide (BP), Immunoprecipitation (IP)
    Spezifität
    This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
    Produktmerkmale

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Aufreinigung
    Purified antibody.
    Reinheit
    > 98 % as determined by SDS-PAGE
    Endotoxin-Niveau
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    Immunogen
    This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
    Klon
    HL22
    Isotyp
    IgG kappa
  • Applikationshinweise
    Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
    Kommentare

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    CD22 (Epratuzumab Biosimilar)
    Abstract
    CD22 (Epratuzumab Biosimilar) Produkte
    Synonyme
    SIGLEC-2 antikoerper, SIGLEC2 antikoerper, CD22 molecule antikoerper, CD22 antikoerper
    Substanzklasse
    Biosimilar
    Hintergrund
    Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
    UniProt
    P20273
Sie sind hier:
Kundenservice